Daewoong's antipyretic unable to get insurance benefits

13 October 2020 - Daewoong Pharmaceutical has failed to list Fiblast (trafermin), a burn treatment drug developed by Japan's Kaken ...

Read more →

Will Tagrisso win insurance benefits in Korea, too?

14 September 2020 - AstraZeneca’s Tagrisso, targeted therapy for lung cancer, has won recognition as the first-line standard treatment for ...

Read more →

‘Korea should introduce indication-specific drug pricing’

31 August 2020 - “Korea must introduce a system to apply different prices for a drug’s multiple indications, to guarantee ...

Read more →

Drug makers to sue government for limiting choline alfoscerate benefit

27 August 2020 - Manufacturers of choline alfoscerate, a dementia drug, are reportedly preparing to file an administrative lawsuit against ...

Read more →

Takeda expects more effective IBD treatment with Kynteles' expanded reimbursement

12 August 2020 - Takeda Korea is strengthening its position in the domestic inflammatory bowel disease market with Kynteles receiving ...

Read more →

Petitioner demands insurance benefit for breast cancer drug Kadcyla

11 August 2020 - A woman has requested that the government grant reimbursement for using Kadcyla of Roche in treating ...

Read more →

Rheumatoid arthritis drug Rinvoq gets insurance benefit

7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit. ...

Read more →

ISPOR announces Virtual ISPOR Asia Pacific 2020

3 August 2020 - ISPOR—The Professional Society for Health Economics and Outcomes Research announced its Virtual ISPOR Asia Pacific 2020 ...

Read more →

Pilot run of herbal medicine reimbursement starts in October

27 July 2020 - The Government said it would run a pilot program to allow herbal medicines to receive the ...

Read more →

'Severe atopic dermatitis drug too expensive for adolescents'

21 July 2020 - The drug regulator expanded approval for Dupixent (dupilumab), a treatment for severe atopic dermatitis, from adults ...

Read more →

Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate

 9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review ...

Read more →

'Xolair’s reimbursement will change treatment paradigm for asthma patients'

9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with ...

Read more →

EMA and Korean Ministry of Food and Drug Safety to share confidential COVID-19 information

30 June 2020 - EMA and the Ministry of Food and Drug Safety of the Republic of Korea have signed ...

Read more →

‘Government should lower prices of generic drugs’

29 June 2020 - “Our policy should aim at reaching the OECD average of general drug use, additionally cut generic ...

Read more →

Dementia drug choline alfoscerate to get limited insurance benefit

12 June 2020 - The government has allowed choline alfoscerate, a dementia drug, to continue to receive the national health ...

Read more →